Can life get any better for Biogen Idec Inc.? Growth in the company's multiple sclerosis (MS) franchise, led by Tecfidera (dimethyl fumarate), and keen interest in an early stage Alzheimer's disease (AD) candidate propelled the big biotech's shares (NASDAQ:BIIB) Friday to a 52-week high of $397.